{"protocolSection": {"identificationModule": {"nctId": "NCT02224274", "orgStudyIdInfo": {"id": "Hypothermia: Clopi vs Tica"}, "organization": {"fullName": "University Medical Centre Ljubljana", "class": "OTHER"}, "briefTitle": "Antiplatelet Therapy After Cardiac Arrest", "officialTitle": "Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia"}, "statusModule": {"statusVerifiedDate": "2018-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-08"}, "primaryCompletionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-08-19", "studyFirstSubmitQcDate": "2014-08-22", "studyFirstPostDateStruct": {"date": "2014-08-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-01-23", "resultsFirstSubmitQcDate": "2018-10-17", "resultsFirstPostDateStruct": {"date": "2019-02-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-17", "lastUpdatePostDateStruct": {"date": "2019-02-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Marko Noc", "investigatorTitle": "Marko Noc, MD, PhD", "investigatorAffiliation": "University Medical Centre Ljubljana"}, "leadSponsor": {"name": "University Medical Centre Ljubljana", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients. The reasons for this are probably slower gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take action. Since ticagrelor has faster intestinal absorption and no need for liver metabolism we expect its effect to be good even in patients with therapeutic hypothermia after cardiac arrest. Patients treated with therapeutic hypothermia after cardiac arrest and percutaneous coronary intervention will be randomised into two groups. One will be treated with ASA and clopidogrel and the other with ASA and ticagrelor. Blood samples will be collected before and 2, 4, 12, 22 and 48 hours after P2Y12 inhibitor administration. Platelet function will be measured by VerifyNow P2Y12 assay and by Multiplate ADPTest. Differences between the groups will be analysed.\n\nHypothesis: Antiplatelet therapy with ticagrelor is more effective than therapy with clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia and percutaneous coronary intervention (PCI)."}, "conditionsModule": {"conditions": ["Cardiac Arrest", "Postresuscitation Syndrome", "Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)"], "keywords": ["Antiplatelet Therapy", "Cardiac Arrest", "Therapeutic hypothermia", "Myocardial infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 57, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Clopidogrel", "type": "ACTIVE_COMPARATOR", "description": "These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.", "interventionNames": ["Drug: Clopidogrel"]}, {"label": "Ticagrelor", "type": "EXPERIMENTAL", "description": "These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.", "interventionNames": ["Drug: Ticagrelor"]}], "interventions": [{"type": "DRUG", "name": "Clopidogrel", "armGroupLabels": ["Clopidogrel"], "otherNames": ["Clopidogrel (Plavix)"]}, {"type": "DRUG", "name": "Ticagrelor", "armGroupLabels": ["Ticagrelor"], "otherNames": ["Ticagrelor (Brilique)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "VerifyNow P2Y12Test - Platelet Reactivity", "description": "Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as \\>208 PRU.", "timeFrame": "12 h after P2Y12 inhibitor loading"}], "secondaryOutcomes": [{"measure": "VerifyNow P2Y12Test - % Inhibition", "description": "% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as \\<11% inhibition.", "timeFrame": "12 hours after P2Y12 inhibitor loading"}, {"measure": "Multiplate ADP Test", "description": "Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.\n\nHigh on-treatment platelet reactivity was defined as \\>46 U.", "timeFrame": "12 hours after P2Y12 inhibitor loading"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female and male over 18 years old\n* Unconscious survivors of cardiac arrest treated with therapeutic hypothermia\n* Acute coronary syndrome (NSTEMI or STEMI) as a reason of cardiac arrest\n* PCI with stent implantation\n* Provision of informed consent prior to any study specific procedures is impossible because subjects are unconscious at the moment of inclusion\n\nExclusion Criteria:\n\n* Use of any P2Y12 inhibitors in last 10 days\n* Use of prasugrel before and 48 hours after loading dose of P2Y12 inhibitor\n* Use of eptifibatide before and 48 hours after loading dose of P2Y12 inhibitor\n* Thrombocytopenia (\\<50\\*109/L)\n* Allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor\n* Ticagrelor contraindications: previous intracranial bleeding, active pathological bleeding, moderate to severe hepatic impairment, heart rate \\< 40/min at presentation\n* Suspected or confirmed pregnancy\n* Use of bivalirudin before and 48 hours after loading dose of P2Y12 inhibitor", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University Medical Centre Ljubljana", "city": "Ljubljana", "zip": "1000", "country": "Slovenia", "geoPoint": {"lat": 46.05108, "lon": 14.50513}}]}, "referencesModule": {"references": [{"pmid": "24800722", "type": "BACKGROUND", "citation": "Steblovnik K, Blinc A, Bozic-Mijovski M, Kranjec I, Melkic E, Noc M. Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention. 2015 Apr;10(12):1418-24. doi: 10.4244/EIJY14M05_02."}, {"pmid": "23890998", "type": "BACKGROUND", "citation": "Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26. Erratum In: Lancet. 2014 Mar 29;383(9923):1128."}, {"pmid": "19923168", "type": "BACKGROUND", "citation": "Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18."}, {"pmid": "17161902", "type": "BACKGROUND", "citation": "Gorjup V, Radsel P, Kocjancic ST, Erzen D, Noc M. Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation. Resuscitation. 2007 Mar;72(3):379-85. doi: 10.1016/j.resuscitation.2006.07.013. Epub 2006 Dec 11."}, {"pmid": "11856794", "type": "BACKGROUND", "citation": "Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002 Feb 21;346(8):557-63. doi: 10.1056/NEJMoa003289."}, {"pmid": "23591428", "type": "BACKGROUND", "citation": "Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos K, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Response to letter regarding article, \"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction\". Circ Cardiovasc Interv. 2013 Apr;6(2):e29. doi: 10.1161/CIRCINTERVENTIONS.113.000134. No abstract available."}, {"pmid": "22890586", "type": "BACKGROUND", "citation": "Souckova L, Opatrilova R, Suk P, Cundrle I Jr, Pavlik M, Zvonicek V, Hlinomaz O, Sramek V. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013 Mar;69(3):309-17. doi: 10.1007/s00228-012-1360-0. Epub 2012 Aug 14."}, {"pmid": "20727659", "type": "BACKGROUND", "citation": "Bjelland TW, Hjertner O, Klepstad P, Kaisen K, Dale O, Haugen BO. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010 Dec;81(12):1627-31. doi: 10.1016/j.resuscitation.2010.07.002. Epub 2010 Aug 19."}, {"pmid": "19535947", "type": "BACKGROUND", "citation": "Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Reasons for exclusion were intraprocedural eptifibatide/thrombolysis (11), decision of attending physician (8) and bradycardia (1)", "recruitmentDetails": "Recruitment from August 2014 to May 2016 at UMC Ljubljana, Slovenia, Europe", "groups": [{"id": "FG000", "title": "Clopidogrel", "description": "These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.\n\nClopidogrel"}, {"id": "FG001", "title": "Ticagrelor", "description": "These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.\n\nTicagrelor"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Clopidogrel", "description": "These patients were treated with clopidogrel 600 mg loading and than 75 mg/24 h."}, {"id": "BG001", "title": "Ticagrelor", "description": "These patients were treated with ticagrelor 180 mg loading and than 90 mg/12 h."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "36"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "64", "spread": "9"}, {"groupId": "BG001", "value": "61", "spread": "12"}, {"groupId": "BG002", "value": "62", "spread": "11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "30"}]}]}]}, {"title": "ST-Elevation Myocardial Infarction in postresuscitation ECG", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "VerifyNow P2Y12Test - Platelet Reactivity", "description": "Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as \\>208 PRU.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "PRU", "timeFrame": "12 h after P2Y12 inhibitor loading", "groups": [{"id": "OG000", "title": "Clopidogrel", "description": "These patients were treated with clopidogrel 600 mg loading and than 75 mg/24 h."}, {"id": "OG001", "title": "Ticagrelor", "description": "These patients were treated with ticagrelor 180 mg loading and than 90 mg/12 h."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "238", "spread": "67"}, {"groupId": "OG001", "value": "101", "spread": "75"}]}]}]}, {"type": "SECONDARY", "title": "VerifyNow P2Y12Test - % Inhibition", "description": "% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as \\<11% inhibition.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% inhibition", "timeFrame": "12 hours after P2Y12 inhibitor loading", "groups": [{"id": "OG000", "title": "Clopidogrel", "description": "These patients were treated with clopidogrel 600 mg loading and than 75 mg/24 h."}, {"id": "OG001", "title": "Ticagrelor", "description": "These patients were treated with ticagrelor 180 mg loading and than 90 mg/12 h."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4", "spread": "11"}, {"groupId": "OG001", "value": "55", "spread": "32"}]}]}]}, {"type": "SECONDARY", "title": "Multiplate ADP Test", "description": "Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.\n\nHigh on-treatment platelet reactivity was defined as \\>46 U.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "U", "timeFrame": "12 hours after P2Y12 inhibitor loading", "groups": [{"id": "OG000", "title": "Clopidogrel", "description": "These patients were treated with clopidogrel 600 mg loading and than 75 mg/24 h."}, {"id": "OG001", "title": "Ticagrelor", "description": "These patients were treated with ticagrelor 180 mg loading and than 90 mg/12 h."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28", "spread": "17"}, {"groupId": "OG001", "value": "15", "spread": "10"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From the date of randomization until hospital discharge or death during hospitalization.", "eventGroups": [{"id": "EG000", "title": "Clopidogrel", "description": "These patients were treated with clopidogrel 600 mg loading and than 75 mg/24 h.", "deathsNumAffected": 7, "deathsNumAtRisk": 16, "seriousNumAffected": 7, "seriousNumAtRisk": 16, "otherNumAffected": 10, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Ticagrelor", "description": "These patients were treated with ticagrelor 180 mg loading and than 90 mg/12 h.", "deathsNumAffected": 9, "deathsNumAtRisk": 20, "seriousNumAffected": 9, "seriousNumAtRisk": 20, "otherNumAffected": 10, "otherNumAtRisk": 20}], "seriousEvents": [{"term": "Death", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 20}]}, {"term": "Bleeding Academic Research Consortium (BARC) 3a and 5", "organSystem": "Surgical and medical procedures", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 20}]}, {"term": "Stent thrombosis", "organSystem": "Surgical and medical procedures", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Cerebrovascular insult", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}], "otherEvents": [{"term": "Aspiration Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 20}]}, {"term": "Minor bleeding", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Bradycardia/asystoly", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}, {"term": "Arterial embolism", "organSystem": "Vascular disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 20}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 20}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Did not address effectiveness of prasugrel. Not powered to address stent thrombosis or bleeding."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Marko Noc", "organization": "UMC Ljubljana", "email": "marko.noc@mf.uni-lj.si", "phone": "+386 1 522 22 96"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000006323", "term": "Heart Arrest"}, {"id": "D000072657", "term": "ST Elevation Myocardial Infarction"}, {"id": "D000072658", "term": "Non-ST Elevated Myocardial Infarction"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}], "browseLeaves": [{"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M1072", "name": "ST Elevation Myocardial Infarction", "asFound": "ST Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M9411", "name": "Heart Arrest", "asFound": "Cardiac Arrest", "relevance": "HIGH"}, {"id": "M10085", "name": "Hypothermia", "relevance": "LOW"}, {"id": "M1073", "name": "Non-ST Elevated Myocardial Infarction", "asFound": "Non-ST Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077144", "term": "Clopidogrel"}, {"id": "D000077486", "term": "Ticagrelor"}], "ancestors": [{"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000058921", "term": "Purinergic P2Y Receptor Antagonists"}, {"id": "D000058919", "term": "Purinergic P2 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1669", "name": "Clopidogrel", "asFound": "Adjuvant", "relevance": "HIGH"}, {"id": "M1812", "name": "Ticagrelor", "asFound": "Immediate", "relevance": "HIGH"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M29294", "name": "Purinergic P2Y Receptor Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}